$$ Advanced Cell Technology $$

Advanced Cell Technology, Inc.
WKN: A0F5H7
US-Kürzel: ACTC
www.advancedcell.com

Totalverlust möglich. Dies stellt keine Kauf- oder Verkaufsempfehlung dar, sondern spiegelt nur meine Meinung wieder. Jeder handelt auf eigenes Risiko. Streng limitieren!

Advanced Cell Technology ist ein Biotechnologieunternehmen, dessen Hauptaugenmerk in der Stammzellenforschung liegt.

ACTC fiel mir in den letzten Wochen durch äusserst regen Handel auf. Hier die Umsatzliste:
09/06/2006 0.810 5,753,373
09/05/2006 0.600 1,711,427
09/01/2006 0.710 2,516,230
08/31/2006 0.610 4,213,036
08/30/2006 0.780 1,540,600
08/29/2006 0.860 2,549,536
08/28/2006 0.890 3,531,320
08/25/2006 0.960 9,995,140
08/24/2006 1.600 15,436,280
08/23/2006 1.830 8,756,230
08/22/2006 0.400 239,478
08/21/2006 0.261 114,131
08/18/2006 0.290 110,964
08/17/2006 0.280 165,338
08/16/2006 0.300 110,950
08/15/2006 0.300 121,151
08/14/2006 0.325 120,927
08/11/2006 0.300 73,607
08/10/2006 0.320 33,068
08/09/2006 0.320 94,179
08/08/2006 0.360 84,782
08/07/2006 0.340 76,497
08/04/2006 0.340 63,200
08/03/2006 0.350 319,761
08/02/2006 0.321 103,008
08/01/2006 0.400 60,490

Die Handelssteigerung dürfte auf den äußerst positiven Newsflow basieren. Alleine gestern mehrere Meldungen:

http://biz.yahoo.com/bw/060906/20060906005238.html?.v=1

http://biz.yahoo.com/bw/060906/20060906005783.html?.v=1

http://biz.yahoo.com/bw/060906/20060906005786.html?.v=1

Dazu bildete sich ein einwandfreies "W" im Chart. Auch three Kings genannt.

ACTC dürfte sich nicht mehr lange unterhalb des Dollars aufhalten...  

...sei es erstmals gelungen, embryonale Stammzellen von menschlichen Embryonen zu gewinnen, ohne den menschlichen Embryo zu zerstören.
Das gelang meines Wissens nach noch keinem Biotechunternehmen!

Warum gelte die Meldung aus den vergangenen Tagen als Sensation auf dem Gebiet der Stammzellenforschung? Bisher habe die Gewinnung von Stammzellen die Zerstörung des Embryos bedeutet. Nun habe aber das Forschungsteam um Robert Lanza von Advanced Cell Technology die Hoffnung geweckt, Stammzellen ohne die Zerstörung des Embryos zu gewinnen. Die Methode des Teams sei es, dem Embryo im frühen Acht- oder Zehn-Zellstadium eine Zelle zu entnehmen und anschließend den Embryo wieder unbeschadet in den Mutterleib zu verpflanzen. Mit den passenden embryonalen Stammzellen lasse sich Körpergewebe jeglicher Art für sich selbst oder kranke Geschwister züchten. Forscher würden hoffen, dass künftig mit Hilfe von Stammzellen neue Adern, Gehirnzellen, Knochen oder sogar ganze Organe gezüchtet werden könnten. Damit würden sich schwere Krankheiten wie Parkinson, Krebs oder Diabetes erfolgreich bekämpfen lassen.


Hier grafisch dargestellt:  

interessanter Wert, ist bei mir auf Watch....Meldung über Erfolg war wohl übereilt.


Analysis: Stem cell method questioned
By STEVE MITCHELL
UPI Senior Medical Correspondent
WASHINGTON, Sept. 6 (UPI) -- Advanced Cell Technology's technique for harvesting embryonic stem cells without harming embryos first reported two weeks ago continues to be enveloped in controversy because scientists say more research is needed to show the method is safe for embryos.

However, the journal Nature, which published the study, is standing behind it, and Advanced Cell says the criticisms are stemming from a misunderstanding of their research.

Advanced Cell, which published the results in the Aug. 24 online version of Nature, has seen their stock rise and fall after the study came out. Shares were up more than 400 percent immediately after the study was released but have come down since and were up 35 percent in late Wednesday trade. The company also lined up $13.5 million in additional funding from investors, but that does not appear to be tied to the results of the study.

Although the technique was initially hailed as providing a way around moral objections to stem cell research, the embryos used in the study actually were destroyed, leading some scientists and critics to suggest that the study does not show the process is safe for embryos.

In the study, Advanced Cell showed a technique called preimplantation genetic diagnosis, routinely used at fertilization clinics, could be used to pluck out or biopsy a single cell from an early-stage embryo and give rise to an embryonic stem cell line.

The PGD technique, which is used to screen for genetic disorders, has been used thousands of times and apparently does not harm the embryo, which can then be implanted in the womb where it develops normally.

Andy LaBarbera, a professor in the University of Cincinnati's obstetrics and gynecology department, said the study was promising, but there were still some unanswered questions about whether it would actually spare the embryo and the efficiency of the technique.

"It's touted as, 'Look, you can make human embryonic stem cell lines without destroying embryos,' but, point in fact, they did destroy the embryos," LaBarbera, who also serves as scientific director for the American Society for Reproductive Medicine, told United Press International.

"The big question here is, 'If you were to go and biopsy a blastomere the same way you do in PGD, would that single cell develop into a stem cell line?'" LaBarbera said. "The answer is that has not been demonstrated," he said.

But at the same time, LaBarbera acknowledged, "Our impressions are that it would not harm the embryo." He noted that PGD has led to about 2,000 live births, indicating the technique leaves the embryo unharmed. In addition, some fertilization clinics already extract two cells, instead of only one, from the embryo for PGD, suggesting that extracting one cell for genetic screening and one cell to give rise to an embryonic stem cell line is theoretically possible.

LaBarbera questioned the efficiency of the technique, saying the study does not give a clear indication of how many embryos or biopsied cells were required to generate a stem cell line.

But he added that the technique could most certainly be made more efficient with some tweaking in the lab.

"I presume with practice and refining conditions, that will become a highly efficient process," he said. "I don't have any doubt about that."

Other scientists have echoed similar criticisms, and Sen. Arlen Specter, R-Pa., during a hearing Wednesday, chastised Advanced Cell for exaggerating their finding and making it more difficult to get legislation passed that would ease restrictions on federal funding for stem cell research.

But Advanced Cell has not backed down in refuting the critiques.

Robert Lanza, the company's vice president of research and scientific development, said the science was sound and the biopsy technique they used was precisely the same method used for PGD.

"The whole point was to address a medical and scientific question, which is if you have a cell biopsied for PGD, does it have the potential to make stem cells?" Lanza told UPI. "The answer is yes," he said.

"Everybody is now saying it's a big leap of faith ... but that's ridiculous, that's absurd," Lanza said.

The reason for the confusion, Lanza said, is his research team was short on embryos, which made it necessary to go in and biopsy embryos multiple times to have enough data to show the biopsied cells had the potential to give rise to embryonic stem cell lines.

The leftover embryos were discarded because it was already known that embryos survive this procedure, via the experience with PGD-biopsied embryos that have resulted in successful pregnancies, so it was not necessary to demonstrate that finding again for this study, he said. Multiple biopsying would not be done if this technique were used in a real-world setting, he noted.

As far as the efficiency of the technique, Lanza said that with the better grade embryos it was roughly equivalent to the efficiency of conventional techniques for obtaining embryonic stem cells.

Nature also defended the validity and importance of the study and its decision to publish it.

"The paper was rigorously peer reviewed by three reviewers, whom supported publication after revisions were made," Natalie DeWitt, the Nature editor who worked on the Advanced Cell study, told UPI.

"Why did Nature publish it?" DeWitt said. "As a potentially important new technique for isolating human (embryonic stem) cells, and the first demonstration that a single blastomere could form human (embryonic stem) cells, the findings were innovative and important enough to publish in Nature."


 

In an effort to have Congress and the President consider funding stem cell lines generated through Advanced Cell Technology's method, Dr. Green stated, "If Congress were to approve legislation that funded research on lines generated by this new method, and if President Bush were to permit such legislation to pass into law, both the members of Congress and the President could honestly turn to the American people and say that no human embryo ever again needs to be harmed or destroyed to produce the stem cell lines we need for federally funded research."

http://biz.yahoo.com/bw/060906/20060906005783.html?.v=1

Auch hier ist zu lesen: ...This technique is not harmful to embryos...

http://biz.yahoo.com/bw/060906/20060906005786.html?.v=1  

in diesem bereich der forschung sind viele scharlatane unterwegs, die gerne ihre forschungsergebnisse fälschen,die dann hinterher keiner prüfung standhalten.
man sollte bedenken das es dabei um viel kohle geht und wer der erst ist kriegt wohl dann auch ein grosses stück vom kuchen.das weckt also begehrlichkeiten und ich bin der meinung das erst jemand erfolg hat wenn dies unabhängig bestätigt ist.
in dem fall bleibt es ein risikoreicher zock.  

dem Kurs juckts nicht :)

+20 % heute  

die leute sind an der börse um geld zu verdienen und das muß nicht immer mit firmen sein die auch wircklich potential haben.
in der branche zählt vor allem phantasie und weniger echte ergebnisse, weil die in der branche einfach noch keiner so richtig hat, das macht sie aber ebend auch ineressant zum zocken, denn wenn du die firma ausgepickt hast die als erstes nachprüfbare ergebnisse vorlegt, dann hast du die eierlegende wollmilchsau.
für mich gehören die aber in die höchste risikoklasse.
das heißt aber nicht das man nicht schon vorher geld damit verdienen kann.  

die branche steht zur zeit ziemlich im blickpunkt vieler aktienbriefe, in den letzten tagen habe ich mehrere empfehlungen zu HLUN bekommen.
arbeiten auch im bereich stammzellen forschung, zwar nicht im grundlagen bereich aber in der anwendung, schwerpunkte sind da übergewicht,plastische und widerherstellende chirurgie. in dem bereich schätz man ein marktvolumen von 15brd.$.
ist schon ein fetter zukunftsmarkt, aber ich warte lieber die erste zockerwelle ab, der einstieg ist später zu günstigeren kursen möglich. den konkrete zahlen legt noch keiner der aspiranten vor, wenn die kommen sollte man aber mit ein oder zwei positionen dabei sein.
 

Moin Gang!

*smile*  

was hat dich zum einstieg für heute bewegt?
gabs news?  

Erstens fand ich hier nett, und außerdem mach ich alles Calibra nach, das weißt du doch...

;)








Ein kleiner Scherz *lol*



 

da börse zu 90% von gefühlen lebt ist das schon ok, ich werd noch abwarten.
mein gefühl sagt das es noch down geht.
1. melde mich wenn sich mein gefühl ändert!
2. melde mich nie wieder wenn ich mich irre! ;))))  

Diese aktie könnte 2008 der Renner werden,wenn Bush erstmal abgewählt ist dürfte es für die Stemcellaktien ein Revival geben.

Chalifmann  

December 17 - Advanced Cell Technology, Inc. Increases Funding Commitment to $1 Million Advanced Cell Technology, Inc.  announced that its technology platform,

which utilizes a single cell biopsy that does not destroy the embryo,

is well positioned to receive Federal funding under the new administration led by President-Elect Barrack Obama.

The Company has the only technology that can produce stem cell lines of all types without the destruction of the embryo.

Funding of these types of technologies is expected to be a high priority of the incoming Administration.  "We believe there is no technology available for clinical use today except the Company's platform which utilizes stem cell derived therapies," said William M. Caldwell IV, Chairman and CEO of Advanced Cell Technology, Inc. "As a result, our technology has generated interest from both domestic and international companies seeking to capitalize on the role that stem cells can play in a broad range of regenerative medicines.

We continue to explore partnering opportunities while focusing on filing an IND next year for our retinal pigment epithelium (RPE) cells program."

Earlier this month, the Company announced the formation of a new international joint venture.

The new company - Allied Cell Technology - will develop human blood cells and other clinical therapies based on ACTC's proprietary hemangioblast cell technology.

ACTC will exclusively license to the joint venture, which will be majority owned by CHA Biotech Co, Ltd. (CHA), all of its hemangioblast technology.

CHA will contribute working capital for the venture as well as paying Advanced Cell a license fee of $500,000. 

 

watch also STEM !!!

 

Non-Dilutive Financing To Be Utilized to Support Clinical Activities Surrounding RPE Cells Program


WORCESTER, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTC:ACTC) announced today that it has entered into a license with Ireland-based Transition Holdings, Inc, for certain of its non-core technology. Under the agreement, Transition agreed to acquire a license to the technology for $2.5 million, which includes the extinguishment of $1.5 million of debt and an additional funding commitment of $1 million. The intellectual property does not relate to any of the Company’s advanced clinical programs. The Company expects to apply the proceeds it receives in the future towards its retinal pigment epithelium (RPE) cells program.

“We are pleased to monetize this intellectual property in a way that raises non-dilutive capital for our shareholders,” said William M. Caldwell IV, Chairman and CEO of Advanced Cell Technology, Inc. “During a period when the capital markets remain highly challenging, particularly for small companies, we have been able to advance our clinical programs through funding from strategic partners like CHA Biotech Co, Ltd. and by the licensing of intellectual property unrelated to our core platform technologies.”

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine with its laboratory located in Worcester, Massachusetts.

For more information, visit www.advancedcell.com  

WORCESTER, Mass.--(BUSINESS WIRE)--The joint venture between Advanced Cell Technology, Inc. (OTC:ACTC - News) and leading Korean-based biotechnology company CHA Biotech Co, Ltd. (CHA), announced today that the company would be named “Stem Cell & Regenerative Medicine International.”

The partnership between Seoul-based CHA and Worcester, Massachusetts-based ACTC is an indication of the accelerating globalization of biotechnology, the company said. The formation of the new international joint venture to develop stem cell technologies based on ACTC’s proprietary hemangioblast cell technology was announced December 1.

Dr. Robert Lanza, head of ACTC’s retinal program and the joint venture’s Chief Scientific Advisor, said the new name captures the essence and scope of what the company is focused on in the most simple and obvious way.

The new company will be located in Worcester, MA and will focus on development of human blood cells and other clinical therapies. It is majority owned by CHA. ACTC will exclusively license all of its hemangioblast technology to the joint venture.  

Eines der weltweit führenden Unternehmen in der Stammzell-Entnahme. In der Forschung glänzend, ist aber derzeit kaum abzusehen, wie sich die Firma entwickeln wird. Staatliche Interessen könnten sich mit dem anstehenden Regierungwechsel enorm verbessern. Schlafender Riese oder Blindgänger?

Gruß, TexX  

December 4, 2008

Advanced Cell Technology, Inc. (“ACT”) (OTC: ACTC), announced today that their study investigating the feasibility of producing functional, oxygen-carrying red blood cells (RBCs) from mature human embryonic stem cells (hESCs) has been formally published in the print version of the prestigious medical journal Blood – the leading publication in the field of hematology. The study,which was previously only available in the online edition of the Journal, includes commentary from Dr. Eric Bouhassira of the Albert Einstein College of Medicine, a leading researcher in the field of hematology.

“This is a major milestone for embryonic stem cell development,” said William Caldwell, CEO and Chairman of ACTC. “These cells were originally derived from hESC’s that were developed using ACT’s single blastomere technique. The company was the first to derive hemangioblast from hESC’s, a result which has yet to be replicated outside of the ACT laboratories. The study shows that ACT can produce these cells in quantity, which as Dr. Bouhassira states in his commentary, is a critical step towards being able to produce a donor-less source of blood for transfusion in the future.”

The study also demonstrated that the process produces viable RBCs with the functional properties of their naturally occurring counterparts, demonstrating that the created cells can be enucleated in vitro. “We show that up to 65% of the blood cells underwent multiple maturation events that resulted in the extrusion of the nucleus,” stated Shi-Jiang Lu, Ph.D., Director of Differentiation for Allied Cell Technology, the Company’s recently announced joint venture with CHA Biotech Co. Ltd. and first author of the paper. “They formed enucleated erythrocytes with a diameter of 6-8 μm, which is similar to normal red blood cells. We also showed that the cells could express adult β-globin and respond normally to biochemical changes.”

The study appears in the December 2008, Volume 112 edition of Blood, a weekly medical journal published by the American Society of Hematology.

Recently, Advanced CEll and CHA Biotech Co, Ltd. (CHA), a leading Korean-based biotechnology company focused on the development of stem cell technologies, announced the formation of a new international joint venture. The new company – Allied Cell Technology – will develop human blood cells and other clinical therapies based on ACTC’s proprietary hemangioblast cell technology. ACTC will exclusively license to the joint venture, which will be majority owned by CHA, all of its hemangioblast technology. CHA will contribute working capital for the venture as well as paying Advanced Cell a license fee of $500,000.  

... Hat sich hervorragend entwickelt, und das bei der gedrückten Börsenstimmung in der vergangenen Woche. Keine nennenswerten News, aber in der Stammzell-Forschung scheint die Phantasie wieder zu bewegen...  

bei der Stammzellforschung. Obama räumt dieser Technologie einiges Gewicht ein, das dürfte den Sektor insgesamt beflügeln:

"# Advance the Biomedical Research Field: Support investments in biomedical research, as well as medical education and training in health-related fields. Fund biomedical research, and make it more efficient by improving coordination both within government and across government/private/non-profit partnerships.
# Advance Stem Cell Research: Support increased stem cell research. Allow greater federal government funding on a wider array of stem cell lines."
http://www.whitehouse.gov/agenda/technology/

Das Fragezeichen, das ich hier sehe und warum ich (noch?) nicht investiert bin ist, dass Advanced Cell Technology eine kleine Firma ist, bei der ich mich frage, ob sie die notwendigen Investitionen langfristig stemmen kann. Falls sich hier ein finanzkräftiger Partner findet, werde ich vermutlich einsteigen.  

von 2 Cent auf 10 Cent gestiegen ! aber was mich am meisten stören würde,ist,negen thunfischpizzas Bedenken,dass die offenbar nicht mal in der Lage sind ein OTCBB Listing auf die reihe zu kriegen,ich habe nämlich eine natürliche abneigung gegen Pink-sheet-Werte ! Und was ist jetzt mit der zerstörungsfreien entnahme von embionic stemcells,immer noch umstritten oder ist mittlerweile klar,dass das klappt ... ?

MFG
Chali  

Nicht schlecht der Specht,

Das teil performt momentan besser als Geron & Co........

MFG
Chali  

Kommende Ausgabe (Februar 09)

Gruß, TexX  

http://washingtontimes.com/news/2009/feb/06/...ntees-aiding-stem-cell

The Washington Times - Feb 05 8:33 PM

WILLIAMSBURG - President Obama on Thursday gave lawmakers his "guarantee" he will sign an executive order overturning President Bush's embryonic stem cell research policy.

Meeting with House Democrats holding a retreat here, Mr. Obama answered a question from Rep. James R. Langevin, a Rhode Island Democrat who is a paraplegic, by saying he will sign the order, according to three sources who were in the closed-door part of the meeting.

"I guarantee you that we will sign an executive order for stem cells," Mr. Obama said, according to the sources who requested anonymity because they were not authorized to talk about the closed-door portion of the meeting.

Mr. Obama said the executive order would be coordinated with Congress on timing, and said it was important that Congress also pass a law codifying his order so that a future president couldn't simply reverse the policy back.

...

Gruß, TexX  

... vom 7.2.2009

http://www.cnn.com/2009/POLITICS/02/07/stimulus.cuts/index.html

Gruß, TexX